An analysis of FDA-approved drugs for inflammation and autoimmune diseases

Drug Discovery Today

Volumn 20, Issue 8, 2015, Pages 920-923

  Kinch, Michael S ^a   Merkel, Janie ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOLOGICAL PRODUCT; CELL NUCLEUS RECEPTOR; CORTICOSTEROID RECEPTOR; CYTOKINE; G PROTEIN COUPLED RECEPTOR; NEW DRUG; NUCLEAR MOLECULAR ENTITY; RITUXIMAB; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR;

ALLERGY; ARTICLE; ASTHMA; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BIOTECHNOLOGY; CHRONIC INFLAMMATION; DRUG APPROVAL; DRUG INDICATION; DRUG INDUSTRY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; ANIMAL; AUTOIMMUNE DISEASES; DRUG DEVELOPMENT; DRUG EFFECTS; HISTORY; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION; TIME FACTOR; TRENDS; UNITED STATES;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; DRUG APPROVAL; DRUG DISCOVERY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84940614663     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.02.006     Document Type: Short Survey

References (14)

1. S. Ten, and et al. Addison's disease 2001 J. Clin. Endocrinol. Metabol. 86 2001 2909 2922
2. J.M. Pearce Thomas Addison (1793-1860) J. R. Soc. Med. 97 2004 297 300
3. L.J. Hoenig, and W.H. Burgdorf President Kennedy's White House tan JAMA Dermatol. 149 2013 597
4. K.G. White Jane Austen and Addison's disease: an unconvincing diagnosis Med. Hum. 35 2009 98 100
5. Z. Cope Jane Austen's last illness Br. Med. J. 2 1964 182 183
6. L. Wright The Looming Tower 2006 Knopf Doubleday
7. E.G. Biglieri My engagement with steroids: a review Steroids 60 1995 52 58
8. M.S. Kinch The rise (and decline?) of biotechnology Drug Discov. Today 19 2014 1686 1690
9. M.S. Kinch, and et al. An overview of FDA-approved new molecular entities: 1827-2013 Drug Discov. Today 19 2014 1033 1039
10. M.S. Kinch An analysis of FDA-approved drugs for oncology Drug Discov. Today 19 2014 1831 1835
11. J.C.W. Edwards, and et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N. Engl. J. Med. 350 2004 2572 2581
12. G.J. Silverman, and S. Weisman Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy Arthritis Rheum. 48 2003 1484 1492
13. N.E. Abdulla, and et al. Rituximab: current status as therapy for malignant and benign hematologic disorders BioDrugs 26 2012 71 82
14. J. Abraham Developing oncology biosimilars: an essential approach for the future Semin. Oncol. 40 Suppl. 1 2013 S5 S24